Elevai Labs Inc (ELAB) Noticias

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B4 - Prospectus [Rule 424(b)(4)]

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy...

Form DEFR14C - Revised information statement materials, definitive

Form 8-K - Current report

Form 8-K - Current report

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes™.Ongoing...

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

“One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” - BosleyMD® Teams With Start-up...

Form 8-K - Current report

Form PRE 14C - Other preliminary information statements

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the...